Controversy erupts over proposed appointment of Yair Netanyahu to senior WZO board position, disrupting negotiations and unity efforts.
Novo Nordisk makes a bold $9B bid to acquire Metsera, a U.S. biotech firm, in a bid to outpace Pfizer's existing $4.9B deal and regain leadership in the competitive obesity drug market.
Controversy erupts over proposed appointment of Yair Netanyahu to senior WZO board position, disrupting negotiations and unity efforts.
Novo Nordisk makes a bold $9B bid to acquire Metsera, a U.S. biotech firm, in a bid to outpace Pfizer's existing $4.9B deal and regain leadership in the competitive obesity drug market.